Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics

References

• LysakerPHRoeDBuckKDRecovery and wellness amidst schizophrenia: definitions, evidence, and the implications for clinical practiceJ Am Psychiatr Nurses Assoc2010161364221659261
   PubMedGoogle Scholar
• BestMWGuptaMBowieCRHarveyPDA longitudinal examination of the moderating effects of symptoms on the relationship between functional competence and real world functional performance in schizophreniaSchizophr Res Cogn201412909525267939
   PubMedGoogle Scholar
• ValenciaMFresánABarakYJuárezFEscamillaRSaraccoRPredicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcomeNeuropsychiatr Dis Treat2015112339234826396518
   PubMed Web of Science ®Google Scholar
• VenturaJSubotnikKLGuzikLHRemission and recovery during the first outpatient year of the early course of schizophreniaSchizophr Res20111321182321764563
   PubMed Web of Science ®Google Scholar
• JuckelGMorosiniPLThe new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophreniaCurr Opin Psychiatry200821663063918852573
   PubMed Web of Science ®Google Scholar
• NasrallahHATargumSDTandonRMcCombsJSRossRDefining and measuring clinical effectiveness in the treatment of schizophreniaPsychiatr Serv200556327328215746501
   PubMed Web of Science ®Google Scholar
• PinnaFTusconiMBosiaMCavallaroRCarpinielloBCagliari Recovery Group StudyCriteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disordersBMC Psychiatry201313123524294839
   PubMed Web of Science ®Google Scholar
• SuttajitSArunpongpaisalSSrisurapanontMPsychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?Neuropsychiatr Dis Treat20141124712477
   Web of Science ®Google Scholar
• JelastopuluEGiourouEMerekouliasGMestousiAMoratisEAlexopoulosECCorrelation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophreniaBMC Psychiatry201414119725005616
   PubMed Web of Science ®Google Scholar
• AwadAGVorugantiLNThe burden of schizophrenia on caregiversPharmacoeconomics200826214916218198934
   PubMed Web of Science ®Google Scholar
• Caqueo-UrízarAGutiérrez-MaldonadoJMiranda-CastilloCQuality of life in caregivers of patients with schizophrenia: a literature reviewHealth Qual Life Outcomes2009718419747384
   PubMed Web of Science ®Google Scholar
• ScheneAHvan WijngaardenBKoeterMWFamily caregiving in schizophrenia: domains and distressSchizophr Bull19982446096189853792
   PubMed Web of Science ®Google Scholar
• GopalSXuHMcQuarrieKCaregiver burden in schizophrenia: pooled analysis of the involvement evaluation questionnaire data for paliperidone palmitate 3-month formulationValue Health2016193A191
   Web of Science ®Google Scholar
• SimpsonGMA brief history of depot neurolepticsJ Clin Psychiatry1984455 Pt 234
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• StevensGLDawsonGZummoJClinical benefits and impact of early use of long-acting injectable antipsychotics for schizophreniaEarly Interv Psychiatry201610536537726403538
   PubMed Web of Science ®Google Scholar
• CorrellCUCitromeLHaddadPMThe use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidenceJ Clin Psychiatry201677Suppl 312427732772
   PubMed Web of Science ®Google Scholar
• BartzokisGLuPHAmarCPLong acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectorySchizophr Res20111321354121767934
   PubMed Web of Science ®Google Scholar
• KirsonNYWeidenPJYermakovSEfficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs2013746568575
   Google Scholar
• Janssen PharmaceuticalsINVEGA SUSTENNA® (paliperidone palmitate) extended release injectable suspension [prescribing information]2017 Available from: https://www.invegasustenna.com/important-product-informationAccessed August 22, 2017
   Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol201025524725620389255
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol201125568569720615933
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection-prospective year-long follow-up of use in clinical practiceActa Psychiatr Scand20141301465124117209
   PubMed Web of Science ®Google Scholar
• TaylorDMSparshattAO’HaganMDzahiniOPaliperidone palmitate: factors predicting continuation with treatment at 2 yearsEur Neuropsychopharmacol201626122011201727743760
   PubMed Web of Science ®Google Scholar
• SiTZhangKTangJEfficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional studyNeuropsychiatr Dis Treat2015111483149226150719
   PubMed Web of Science ®Google Scholar
• SiTFanJWangXA subgroup analysis of Chinese patients switched to paliperidone palmitate one-month injectable by prior oral antipsychotic treatmentPharmacopsychiatry2016491324126679089
   PubMed Web of Science ®Google Scholar
• OplerMGYangLHCaleoSAlbertiPStatistical validation of the criteria for symptom remission in schizophrenia: preliminary findingsBMC Psychiatry2007713517650312
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRRWhat does the PANSS mean?Schizophr Res2005792–323123815982856
   PubMed Web of Science ®Google Scholar
• RosenKGaretyPPredicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodesSchizophr Bull200531373575016123527
   PubMed Web of Science ®Google Scholar
• DuboisVPeuskensJGeertsPDetrauxJClinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)Early Interv Psychiatry201481394923343330
   PubMed Web of Science ®Google Scholar
• SiTSuYLiuYPharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjectsHum Psychopharmacol201429220321024590546
   PubMed Web of Science ®Google Scholar
• BisharaDOnce-monthly paliperidone injection for the treatment of schizophreniaNeuropsychiatr Dis Treat2010656157220856919
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraACPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophreniaSchizophr Res20151691–339339926431793
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry20111011221481243
   PubMed Web of Science ®Google Scholar
• BossieCASliwaJKMaYWFuDJAlphsLOnset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialBMC Psychiatry20111117921569242
   PubMed Web of Science ®Google Scholar
• LambertMKarowALeuchtSSchimmelmannBGNaberDRemission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years laterDialogues Clin Neurosci201012339340720954433
   PubMedGoogle Scholar
• GharabawiGBossieCTurkozIKujawaMMahmoudRSimpsonGThe impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectableJ Nerv Ment Dis20071951297698218091190
   PubMed Web of Science ®Google Scholar
• TangVWLeungSKLamLCClinical correlates of the caregiving experience for Chinese caregivers of patients with schizophreniaSoc Psychiatry Psychiatr Epidemiol200843972072618438734
   PubMed Web of Science ®Google Scholar
• LiebermanJAPerkinsDBelgerAThe early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approachesBiol Psychiatry2001501188489711743943
   PubMed Web of Science ®Google Scholar
• McGorryPDKillackeyEYungAEarly intervention in psychosis: concepts, evidence and future directionsWorld Psychiatry20087314815618836582
   PubMed Web of Science ®Google Scholar
• WiersmaDNienhuisFJSlooffCJGielRNatural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohortSchizophr Bull199824175859502547
   PubMed Web of Science ®Google Scholar
• CanusoCMBossieCAAmatniekJTurkozIPandinaGCornblattBPaliperidone extended-release tablets in patients with recently diagnosed schizophreniaEarly Interv Psychiatry201041647820199482
   PubMed Web of Science ®Google Scholar
• MacfaddenWBossieCATurkozIHaskinsJTRisperidone long-acting therapy in stable patients with recently diagnosed schizophreniaInt Clin Psychopharmacol2010252758220101185
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar
• PatrickDLBurnsTMorosiniPGagnonDDRothmanMAdriaenssenIMeasuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tabletsClin Ther201032227529220206786
   PubMed Web of Science ®Google Scholar
• SuzukiTWhich rating scales are regarded as ‘the standard’ in clinical trials for schizophrenia? A critical reviewPsychopharmacol Bull2011441183122506437
   PubMedGoogle Scholar
• SuzukiTUchidaHWatanabeKKashimaHTreatment target in schizophrenia: a critical review and a clinical suggestionPsychopharmacol Bull20084148010219015632
   PubMedGoogle Scholar
• JeongHGLeeMSLong-acting injectable antipsychotics in first-episode schizophreniaClin Psychopharmacol Neurosci20131111623678347
   PubMed Web of Science ®Google Scholar
• LlorcaPMAbbarMCourtetPGuillaumeSLancrenonSSamalinLGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry201313134024359031
   PubMed Web of Science ®Google Scholar